Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Relmada Therapeutics ( (RLMD) ) has shared an update.
Relmada Therapeutics has announced the appointment of Paul Kelly as Chief Operating Officer effective January 1, 2025, which is expected to strengthen its leadership team. The company has made strategic adjustments to executive compensation to manage expenses, including suspending retention payments and withholding salary increases and bonuses for fiscal 2025.
More about Relmada Therapeutics
Relmada Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing treatments for central nervous system disorders. The company is committed to advancing therapies that address unmet medical needs in the market.
YTD Price Performance: 4.44%
Average Trading Volume: 953,828
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $14.18M
Learn more about RLMD stock on TipRanks’ Stock Analysis page.
